Amwill Health Care Limited (BSE: 544353) is a Bengaluru, Karnataka-based company in the Pharmaceuticals industry. With a market capitalisation of ₹84 Cr, it ranks #3,304 by market cap among the 6,197 Indian listed companies on FinBizNet, and #45 of 63 in Pharmaceuticals. At ₹43.50 (as of 10 Nov 2026), the share price is 23.7% below its 52-week high of ₹57.00 and 50.5% above its 52-week low of ₹28.91. The share price is down 19.4% over one year and up 4.8% over three months.
| Current Price | ₹43.50 |
|---|---|
| Market Cap | ₹84 Cr |
| BSE Code | 544353 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 7.4 |
| Return on Assets | 9.88% |
| 52-Week Range | ₹28.91 – ₹57.00 |
| 1-Year Price Change | -19.4% |
| 3-Month Price Change | +4.8% |
| Beta (1Y) | 0.5 |
| Dividend Yield | 1.19% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.amwillhealthcare.com |
Delivery averaged 82.4% of traded volume across 13 BSE sessions (15 Oct 2026 – 6 Nov 2026).
Amwill Health Care Limited, a derma-cosmetic company, engages in the development and contract manufacturing of generic dermatological solutions in India. It offers product formulations for anti-acne, dry skin, anti-aging, anti-fungal, anti-histaminic, anti-perspirant, antibiotics, skin lightening, hair care, steroid and keratolytic, sunscreen, vitiligo, miscellaneous, peri-orbital hyperpigmentation, anti-scar, topical antibiotics, antioxidants, and anti-scabies, as well as cosmeceutical and aesthetic categories. The company was founded in 2009 and is headquartered in Bengaluru, India.
1. Dealing in Pharma Products-This segment engages in the development and contract manufacturing of generic dermatological solutions. It is also involved in developing and formulating solutions to specific dermatological problems. 2. NA-NA 3. NA-NA 4. NA-NA
1. Dealing in Pharma Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹54,788 Cr | 35.3 | 34.46% | ₹1,814 Cr | -8.2% |
| Ajanta Pharma Limited | ₹42,432 Cr | 40.2 | 25.39% | ₹1,794 Cr | +35.7% |
| Emcure Pharmaceuticals Ltd | ₹35,726 Cr | 38.6 | 19.57% | ₹2,820 Cr | +67.0% |
| Piramal Pharma Ltd | ₹31,892 Cr | n/m | -4.00% | ₹2,617 Cr | +21.7% |
| RUBICON RESEARCH LIMITED | ₹27,601 Cr | 108.9 | 19.14% | ₹576 Cr | +186.9% |
| Caplin Point Laboratories Ltdte | ₹17,770 Cr | 27.8 | 19.94% | ₹610 Cr | +25.0% |
| Pfizer Ltd. | ₹16,646 Cr | 23 | 17.16% | ₹727 Cr | -24.3% |
| Eris Lifesciences Ltd | ₹16,096 Cr | 25.6 | 18.07% | ₹892 Cr | -21.1% |
| Amwill Health Care Limited | ₹84 Cr | 7.4 | — | — | -19.4% |
Listed by market capitalisation. Ratios are shown for context only.
Amwill Health Care Limited is trading at ₹43.50, with a market capitalisation of ₹84 Cr.
Amwill Health Care Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Amwill Health Care Limited has a P/E of 7.4.
Amwill Health Care Limited is listed on the BSE under the scrip code 544353.
Amwill Health Care Limited's share price is down 19.4% over one year and up 4.8% over three months. Its 52-week range is ₹28.91 to ₹57.00.
Data as of 10 Nov 2026. Descriptive market data only — not investment advice.